Related Experiment Video
Updated: Apr 12, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
Published on: September 25, 2019
Intramuscular hepatitis B immunoglobulins for reinfection control after liver transplantation: a cost-saving
Eva Hulstaert1, Xavier Verhelst1, Anja Geerts1
1Department of Hepatology, University Hospital Ghent, De Pintelaan 185, B9000 Ghent, Belgium.
Aim:
We explore the effectiveness and cost-effectiveness of intramuscular versus intravenous hepatitis B immunoglobulins (HBIG-IV vs HBIG-IM) to prevent reinfection with the hepatitis B virus after orthotopic liver transplantation.
Patients & Methods:
Overall, 14 patients had orthotopic liver transplantation in 2003-2013 at Ghent University Hospital for HBV-related liver disease. On average 32 months after transplantation patients switched from high-dose HBIG-IV to low-dose HBIG-IM, always in combination with a nucleos(t)ide analog.
Results:
Seven patients were switched so far. No significant differences between HBIG-IV and HBIG-IM were found in HBsAg and hepatitis B virus-DNA.
Conclusion:
Switching patients from HBIG-IV to HBIG-IM can be done safely if well monitored. Net yearly savings for the healthcare payer were €5000 for each patient switched to HBIG-IM.
More Related Videos
Related Concept Videos
Hepatitis
Inhibitors of Viral Protein Synthesis

